Early health technology assessment of magnetic resonance-guided high intensity focused ultrasound ablation for the treatment of early-stage breast cancerKnuttel, F. M., Huijsse, S. E. M., Feenstra, T. L., Moonen, C. T. W., van den Bosch, M. A. A. J., Buskens, E., Greuter, M. J. W. & de Bock, G. H., 1-Aug-2017, In : Journal of therapeutic ultrasound. 5, 23
Research output: Contribution to journal › Article › Academic › peer-review
- Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Life Course Epidemiology (LCE)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Value, Affordability and Sustainability (VALUE)
- Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
BACKGROUND: Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) ablation is in development for minimally invasive treatment of breast cancer. Cost-effectiveness has not been assessed yet. An early health technology assessment was performed to estimate costs of MR-HIFU ablation, compared to breast conserving treatment (BCT).
METHODS: An MR-HIFU treatment model using the dedicated MR-HIFU breast system (Sonalleve, Philips Healthcare) was developed. Input parameters (treatment steps and duration) were based on the analysis of questionnaire data from an expert panel. MR-HIFU experts assessed face validity of the model. Data collected by questionnaires were compared to published data of an MR-HIFU breast feasibility study. Treatment costs for tumours of 1 to 3 cm were calculated.
RESULTS: The model structure was considered of acceptable face validity by consulted experts, and questionnaire data and published data were comparable. Costs of MR-HIFU ablation were higher than BCT costs. MR-HIFU best-case scenario costs exceeded BCT costs with approximately €1000. Cooling times and breathing correction contributed most to treatment costs.
CONCLUSIONS: MR-HIFU ablation is currently not a cost-effective alternative for BCT. MR-HIFU experience is limited, increasing uncertainty of estimations. The potential for cost-effectiveness increases if future research reduces treatment durations and might substantiate equal or improved results.
|Journal||Journal of therapeutic ultrasound|
|Publication status||Published - 1-Aug-2017|
- Journal Article, Breast cancer, Cost-effectiveness, Breast-conserving therapy, CONSERVING SURGERY, METAANALYSIS, THERMOMETRY